anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

164,401-164,460 of 319,975

filter-aware
10
Includes logos of four partner organizations.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
11
The slide uses a bulleted list to detail the partnership strategy, focusing on leveraging existing lab infrastructure to minimize marketing overhead.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
12
Includes a map of the US and Europe with color-coded status indicators.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
13
Includes a stock market snapshot of Exact Sciences and a clinical performance comparison table.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
14
Includes a disclaimer at the bottom and a product visualization.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
15
Includes a photo of the office building and a grid of partner/affiliate logos.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
16
The slide lists four key executives: CEO, CFO, COO, and CSO.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
17
Mainz Biomed NV | Investor Presentation Deck | 23 slidesMainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
18
Mainz Biomed NV | Investor Presentation Deck | 23 slidesMainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
19
Mainz Biomed NV | Investor Presentation Deck | 23 slidesMainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
20
The slide serves as a repository for additional information, specifically partner logos and team representation.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
21
Includes a disclaimer at the bottom and a citation for the 85% detection rate.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
22
Mainz Biomed NV | Investor Presentation Deck | 23 slidesMainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
23
The slide includes a specific milestone criterion for February 2022 regarding biomarker specificity.Mainz Biomed NV | Investor Presentation Deck | 23 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
01
Slide 1
Features a molecular structure visualization.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
02
Nuvalent | IPO Presentation Deck | 40 slidesNuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
03
This is a standard IPO deal term sheet slide.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
04
The slide combines a funding timeline on the left with a strategic summary on the right.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
05
Uses a Venn diagram to illustrate the intersection of two critical clinical challenges.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Beat · Solution1 hit
06
Uses a before-after-bridge framework to contrast existing therapy failure with Nuvalent's solution.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Beat · Problem1 hit
07
Uses a visual comparison diagram to explain the mechanism of action and clinical benefit of selectivity.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Beat · Problem1 hit
08
The chart uses a Gantt-style visualization to show progress from discovery through IND enabling phases.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
09
Includes a section on 'Prior FDA Approval Experience' with company logos.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
10
The slide features a 3D molecular rendering showing the inhibitor (pink) bound to the target protein (blue).Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
11
The slide uses a three-part process flow to explain the biological mechanism of ROS1-driven disease and resistance.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
12
The table highlights the clinical limitations of current standard-of-care drugs (Crizotinib, Entrectinib) due to resistance mutations like G2032R and CNS involvement.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Beat · Market Sizing1 hit
13
The table uses a green/white color coding to highlight the competitive advantage of NVL-520.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Beat · Market Sizing1 hit
14
The slide uses a medical illustration to map specific TRK receptor inhibition (TRKB, TRKC, TRKA) to corresponding neurological and physiological side effects.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Beat · Competition1 hit
15
The slide uses a structured table-like layout to define the product profile.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
16
Includes a table of IC50 values and a line chart showing tumor volume over time for different dosages.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
17
Includes a heatmap table for IC50 values and two line charts showing tumor volume reduction in PDX models.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
18
The chart uses a logarithmic scale to show relative selectivity ratios.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
19
The kinome tree is a standard visualization in pharmacology for kinase selectivity.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
20
The slide highlights CNS activity via brain penetration, a key component of the NVL-520 target product profile.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
21
The slide uses bioluminescence imaging to show tumor reduction and a Kaplan-Meier survival curve to show efficacy.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
22
The slide lists specific key opinion leaders (KOLs) and their respective institutions across the US, Spain, France, and the Netherlands.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
23
The slide uses a hybrid layout combining a staircase diagram for Phase 1 and a structured table for Phase 2.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
24
The slide uses a high-quality 3D molecular rendering to illustrate the mechanism of action.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
25
The slide uses a three-column process flow to explain the biological mechanism of ALK-driven cancer and resistance.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
26
The slide highlights the clinical unmet need as patients progress through lines of therapy, specifically noting resistance mutations and CNS involvement.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
27
The table uses a green/white color coding to highlight the superior profile of NVL-655 compared to existing therapies.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
28
The slide uses a structured table format to define the product's key performance characteristics.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
29
The slide uses a color-coded heatmap to indicate potency (green for high potency, yellow for lower).Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
30
Includes a table of IC50 values and two line charts showing tumor volume reduction in CDX models.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
31
The chart uses a logarithmic scale to show fold-selectivity. NVL-655 shows significantly higher selectivity for ALK variants compared to the other two drugs.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
32
The slide uses a kinome tree diagram to visualize selectivity. The table defines the selectivity index based on IC50 ratios.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
33
Includes disclaimer regarding clinical studies and FDA feedback.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
34
Nuvalent | IPO Presentation Deck | 40 slidesNuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
35
The slide uses a hexagonal process flow diagram to illustrate the three-step methodology.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
36
The slide uses a side-by-side comparison structure to highlight the target product profiles for ALK IXDN Resistance Mutations and HER2 Exon 20 Insertions.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
37
Nuvalent | IPO Presentation Deck | 40 slidesNuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
38
The slide uses a dual-track timeline: top for corporate events, bottom for clinical/R&D pipeline progress.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
39
The slide features a 3D molecular structure visualization, likely a protein-ligand complex.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
40
Features company logo and a molecular structure visualization.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank 1 hit
01
Slide 1
Omega Therapeutics | IPO Presentation Deck | 33 slidesOmega Therapeutics | IPO Presentation Deck | 33 slides · Omega Therapeutics
Pitch deck Investment bank 1 hit
02
Omega Therapeutics | IPO Presentation Deck | 33 slidesOmega Therapeutics | IPO Presentation Deck | 33 slides · Omega Therapeutics
Pitch deck Investment bank 1 hit
03
Omega Therapeutics | IPO Presentation Deck | 33 slidesOmega Therapeutics | IPO Presentation Deck | 33 slides · Omega Therapeutics
Pitch deck Investment bank 1 hit
04
Uses a 'What if' rhetorical device to frame the company's core technological thesis.Omega Therapeutics | IPO Presentation Deck | 33 slides · Omega Therapeutics
Pitch deck Investment bank 1 hit
05
The slide uses a hub-and-spoke diagram to illustrate MYC's regulatory reach and a line chart to show efficacy.Omega Therapeutics | IPO Presentation Deck | 33 slides · Omega Therapeutics
Pitch deck Investment bank 1 hit
06
Uses a biological analogy of an 'operating system' to explain gene regulation.Omega Therapeutics | IPO Presentation Deck | 33 slides · Omega Therapeutics
Pitch deck Investment bank 1 hit